ArticleFrontiers in genetics2026
Modifiable risk factors and skin cancers: a multi-omics Mendelian randomization study from causal inference to drug target discovery.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recent studies have linked modifiable risk factors (RFs) to melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). This study aimed to investigate the causal relationships between 11 modifiable RFs and these skin cancers and to identify novel therapeutic targets using multi-omics approaches. Methods: Exposure data were obtained from genome-wide association studies (GWAS). Mendelian randomization (MR) analyses were performed using the inverse variance weighted (IVW) method as the primary approach, and results from discovery and replication cohorts were combined by meta-analysis. Functional Mapping and Annotation (FUMA) and summary-data-based MR (SMR) were used to prioritize therapeutic targets. Drug prediction, phenome-wide association studies (PheWAS), and single-cell analyses were conducted to evaluate target druggability and biological relevance. Results: Actinic keratosis (AK) was associated with an increased risk of melanoma (OR = 1.24, 95% CI 1.07-1.43, P < 0.01), whereas alcohol consumption was negatively associated with SCC risk (OR = 0.77, 95% CI 0.62-0.95, P = 0.02). No causal relationships were observed between the investigated RFs and BCC. One potential therapeutic target for melanoma (EDEM2, PSMR = 0.03) and five candidate therapeutic targets for SCC (MAPK3, PSMR = 5.30E-04; NRBP1, PSMR = 4.32E-04; ANKK1, PSMR = 1.89E-06; IL27, PSMR = 3.04E-03; ADH5, PSMR = 0.02) were identified. Drug prediction, PheWAS, and single-cell analyses further supported the therapeutic potential of these genes. Discussion: AK appears to increase the risk of melanoma, whereas alcohol consumption may be protective against SCC. EDEM2 may represent a potential therapeutic target for melanoma, while MAPK3, NRBP1, ANKK1, IL27, and ADH5 are promising candidate targets for SCC. Further experimental and clinical studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.